How do you pay?

How to pay the least

Ask for the cash price

Wainua

We didn’t find one.

  1. Ask your pharmacy for Wainua’s cash price, and one or two other pharmacies too.
  2. Wainua’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify AZ&Me Prescription Savings Program. For AZ&Me’s Rare Disease product(s) (WAINUA), your annual adjusted gross income must be at or below 500% of the Federal Poverty Level Or call 1-800-292-6363.

See if you qualify 

Compare every option

Question
Brand nameWainua
Authorized genericeplontersen
Regular genericeplontersen
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Wainua?
The original
–
–

Brand nameThe maker’s card

WAINUA Savings Program

Savings card from AstraZeneca

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on wainua.com 

In the maker’s words

“With the WAINUA Savings Program, eligible, commercially insured patients may be able to pay as little as $0 per month for WAINUA.”

From the maker’s offer on wainua.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Wainua itself, from the same company, sold without the brand name, and usually for less. For now Wainua is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

WAINUA is a transthyretin-directed antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Source: the FDA label for Wainua (AstraZeneca Pharmaceuticals LP), April 15, 2026. Full label on DailyMed 

Good to know